publication date: Feb. 28, 2017
Prostate Cancer Regimen Extends Life for Some Men With Recurrent Prostate Cancer
Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with prostate cancer who have had their prostate gland removed, according to a new Cedars-Sinai study published in the Feb. 2 issue of the New England Journal of Medicine.
The regimen also can reduce the frequency of spread of the cancer, the study found. Prostate cancer is the second most common cancer in U.S. men. An estimated 161,300 new cases will be diagnosed and nearly 27,000 deaths are expected in 2017, according to the American Cancer Society.
“Our study indicates that hormonal treatments should be incorporated into the management of men who need radiation therapy after surgery for prostate cancer,” said Howard Sandler, chair of the Department of Radiation Oncology the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai and senior author of the multicenter study.
More than 30 percent of prostate cancer patients face the return of disease one to four years after removal of the prostate gland, Sandler said. When a patient experiences a recurrence, physicians typically prescribe radiation therapy.
“Our results show that adding hormone therapy could add years to patients’ lives,” Sandler said.
The study, which included researchers at 17 medical institutions, tracked 761 prostate cancer patients in the U.S. and … Continue reading CCL Feb 2017 – Regimen Extends Life for Some Men With Recurrent Prostate Cancer
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.